Microsoft, weight loss drug sales, and GSK profits surge


In today’s episode, Ian King speaks with Dan Ives – managing director of the brokerage and advisory firm Wedbush Securities – to discuss Microsoft’s revenues and AI.

Ian Johnston, global pharmaceutical correspondent at the Financial Times, discusses sales of popular weight loss drug ‘Wegvoy’, made by Novo Nordisk – as they say their sales almost quadrupled last year.

And, Ian discusses GSK’s operating profit of £8.8bn for 2023 with strong selling medicines including its HIV and shingles medication.

Articles You May Like

Trump and Biden promise tough action on immigration in rival Texas visits
Google Gemini product lead retreats from social media after troubled AI product launch led to harassment
Tesla loses lead interior designer
Smart, UGA add Coley, Crawford to coaching staff
Mexico writing a new chapter of USWNT rivalry with stunning win in W Gold Cup